Syros Pharmaceuticals, Inc.
SYRS · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.01 | 0.10 | 2.19 |
| FCF Yield | -49.84% | -274.11% | -49.44% | -12.15% |
| EV / EBITDA | -0.91 | 0.67 | -2.22 | -4.95 |
| Quality | ||||
| ROIC | -91.82% | -62.37% | -63.96% | -43.76% |
| Gross Margin | 77.33% | 80.06% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.67 | 1.30 | 1.15 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | -24.93% | -0.47% | 127.99% | 94.54% |
| Free Cash Flow Growth | 11.53% | -23.34% | -66.04% | 16.72% |
| Safety | ||||
| Net Debt / EBITDA | 0.49 | 1.19 | 0.34 | 1.36 |
| Interest Coverage | -25.16 | -32.87 | -25.45 | -45.92 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,871.03 | -747.13 | 46.29 | 56.37 |